Loading…

Boston ScientificBSXCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Global medical device maker specializing in cardiovascular (structural heart, electrophysiology), endoscopy and urology devices.

Momentum weak 33
Mkt cap
$63.3B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$875M
20-day average traded
Fwd P/E
14.1×
forward earnings
ROIC−WACC
+1.9 pp
WACC 7.7%
Hurdle
-9 pp
Req g minus delivered
Official | Implied
A- / A
agencies · bond market
Next earnings
77 days
3 Feb 2027
Close · USD$43.64
1D+1.4%
1W-3.3%
1M-4.3%
3M-11.6%
6M-23.0%
YTD-54.2%
1Y-57.1%
ATR %3.7%
Beta0.30
52w lowhigh57.2% off high

What Boston Scientific does

Global medical device maker specializing in cardiovascular (structural heart, electrophysiology), endoscopy and urology devices.

Sells single-use devices used in each procedure, through its own sales force and clinical staff who train physicians, so revenue follows procedure volume. Hospitals buy under negotiated purchasing contracts. Growth has come partly from bought technology, such as the Farapulse ablation system acquired in 2021, rather than only internal development.

Products and services

  • Cardiology (Watchman, electrophysiology)
  • Endoscopy
  • Urology & pelvic health
  • Neuromodulation

Customers

  • Cardiologists/electrophysiologists
  • Hospitals
  • Urologists/GI specialists

Where it sits in the supply chain

  • Healthcare
  • Medical devices
  • Cardiovascular, endoscopy, urology…

What could go right

  • Watchman LAA-closure adoption growth
  • Electrophysiology (PFA) share gains

What could go wrong

  • Device pricing/reimbursement pressure
  • Product recall/regulatory risk

Moat: wide (IP / patents, switching costs, installed base). Leading positions in structural heart (Watchman) and electrophysiology with strong physician training lock-in.

Headquarters: Marlborough, Massachusetts, USA · Founded: 1979 · Employees: 59,000

Named competitors

Boston Scientific at a glance

Size Boston Scientific (BSX) is a United States Health Care company (Medical Specialties) with a market value of $63.3B, the 209th largest of 3,085 United States companies the cockpit tracks. Shares closed at $43.64 on 18 Nov 2026.

Performance Over six months the shares fell 23.0%, against +26.4% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue grew 8.9% over the last twelve months (peer median +8.8%); the operating margin is 21.4% (peer median 23.5%).

Valuation It trades at 14.1× forward earnings against a peer median of 27.2× (cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -9 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.9 points above its cost of capital (7.7% WACC).

Credit Boston Scientific has 7 bonds outstanding ($4.26B), rated A- by the agencies and trading like A at a weighted spread of 75 bp.

Short interest Short interest is 2.4% of the free float (30 Oct 2026).

Next results Next results expected around 3 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 126BSX 76
Six months, rebased to 100: Boston Scientific against the median of its 20 peers (local-currency closes).

Boston Scientific financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$21.1B$20.1B$16.7B$14.2B$12.7B
Revenue growth—+20%+18%+12%—
Gross profit$13.8B$13.1B$10.3B$8.83B$7.71B
EBITDA$5.95B$5.44B$3.90B$3.38B$2.96B
Net income$3.50B$2.90B$1.85B$1.59B$698M
Free cash flow$3.33B$3.66B$2.65B$1.79B$938M
Capital expenditure$903M$876M$790M$711M$588M
Total debt$12.0B$12.0B$11.2B$9.49B$9.28B

Quarterly statements and history in the cockpit →

Boston Scientific competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%+60%-10%0%+10%+20%EWBDXIDXXSHLMDLNA7741WATELGEHCALCMTDRMD300760SYKILMNMDTDXCMWSTISRGBSX6-month return →1-month return →
Up and to the right = strong over both horizons. Boston Scientific is the large dot.

Fundamentals: revenue growth against valuation

0%+5%+10%+15%+20%20×30×40×EWBDXIDXXSHLMDLNA7741WATELGEHCALCMTDRMD300760SYKILMNMDTWSTISRGBSXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Boston Scientific is the large dot.

Capital: growth delivered against growth the price implies

0%+10%+20%+30%0%10%20%30%EWBDXIDXXSHLMDLNA7741WATELGEHCALCMTDRMD300760SYKILMNMDTDXCMWSTISRGBSXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Boston Scientific is the large dot.

Boston Scientific competitors and peer comparison

Head to head with its named competitors (BSX vs MDT vs ABT vs EW)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Boston Scientific BSX$63.3B-23%+9%21%14.1×5.8%
Medtronic MDT$129B+30%+10%20%16.8×9.1%
Abbott Laboratories ABT$181B+18%+10%14%17.9×16.5%
Edwards Lifesciences EW$60.5B+27%+13%29%32.3×17.1%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%

How Boston Scientific compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Boston Scientific against its 20 peers (data as of 18 Nov 2026)
MeasureBSXPeer medianRank in peer set
1-month return-4.3%+6.1%3rd lowest of 21
6-month return-23.0%+26.4%lowest of 21
Distance from 52-week high-57.2%-9.1%lowest of 21
Revenue growth (TTM)+8.9%+8.8%11th highest of 21
Operating margin21.4%23.5%10th lowest of 21
Forward P/E14.1×27.2×cheapest of 21
Growth the price implies (Req g, 7 yrs)5.8%16.5%5th least demanding of 21
Growth delivered (Del g)+15.2%+7.1%3rd highest of 21
Hurdle (Req g minus delivered)-9.4 pp+5.6 ppleast demanding of 21
ROIC minus cost of capital+1.9 pp+5.9 pp7th lowest of 21
EV / EBITDA12.6×20.2×3rd cheapest of 20
Net debt / EBITDA1.9×1.5×7th most indebted of 20
Bond spread75 bp75 bp5th widest of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Boston Scientific BSXUnited States$63.3B-23%+9%21%14.1×5.8%+15.2%
Edwards Lifesciences EWUnited States$60.5B+27%+13%29%32.3×17.1%+6.7%
Becton Dickinson BDXUnited States$58.9B+48%-7%16%16.3×-1.6%+0.3%
Idexx Laboratories IDXXUnited States$55.0B+26%+12%32%42.9×29.0%+9.7%
Siemens Healthineers SHL.DEGermany$53.7B+27%+1%14%18.9×9.6%+5.6%
Medline MDLNUnited States$51.5B+8%+12%6%25.6×15.9%+9.9%
Agilent Technologies AUnited States$50.0B+56%+9%24%27.0×23.3%+5.4%
Hoya 7741.TJapan$49.0B-16%+13%32%27.7×14.1%+11.6%
Waters WATUnited States$45.8B+37%+81%10%29.1×48.1%+6.0%
EssilorLuxottica EL.PAFrance$91.9B+5%+8%12%24.8×18.4%+14.6%
GE HealthCare GEHCUnited States$37.8B+30%+7%14%15.6×5.0%+3.7%
Alcon ALC.SWSwitzerland$36.9B+18%+1%12%21.5×12.2%+6.1%
Mettler Toledo MTDUnited States$34.6B+60%+7%29%33.7×20.1%+5.5%
ResMed RMDUnited States$34.1B+16%+9%34%19.7×5.7%+12.1%
Shenzhen Mindray Bio-Medical Electronics 300760.SZChina$33.6B+15%+5%28%27.3×1.0%+9.7%
Stryker SYKUnited States$121B-1%+8%25%19.9×10.7%+11.8%
Illumina ILMNUnited States$31.8B+48%+6%21%35.2×27.2%+6.0%
Medtronic MDTUnited States$129B+30%+10%20%16.8×9.1%+3.8%
Dexcom DXCMUnited States$30.8B+16%+13%24%28.0×19.6%+19.3%
West Pharmaceutical Services WSTUnited States$28.1B+32%+13%23%40.2×25.8%+7.4%
Intuitive Surgical ISRGUnited States$146B-6%+20%32%34.8×29.6%+18.2%

Boston Scientific bonds and credit

Boston Scientific has 7 bonds outstanding with $4.26B face value. The agencies rate it A-; its bonds trade like A. Weighted yield 5.14%, a spread of 75 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Boston Scientific's main competitors?
Named competitors: Medtronic (MDT), Abbott Laboratories (ABT), Edwards Lifesciences (EW), Johnson & Johnson (JNJ). The cockpit's measured peer set (industry) also includes Edwards Lifesciences (EW), Becton Dickinson (BDX), Idexx Laboratories (IDXX), Siemens Healthineers (SHL.DE), Medline (MDLN), Agilent Technologies (A).
Is Boston Scientific expensive compared with its peers?
On forward p/e it trades at 14.1× against a peer median of 27.2×, cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -9 pp: the price already allows for a slowdown.
How has Boston Scientific stock performed?
Over six months to 18 Nov 2026 the shares returned -23.0% against +26.4% for the median peer; over one year -57.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.